BrainStorm

News

News

Press Releases

Date Title and Summary Additional Formats
Toggle Summary BrainStorm Cell Therapeutics to make scientific presentations at the 30th International Symposium on ALS/MND
BrainStorm’s Chief Operating and Chief Medical Officer, Ralph Kern MD MHSc, will make a podium presentation at Clinical Trials Session NEW YORK , Nov. 26, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leader in the development of innovative autologous cellular
View HTML
Toggle Summary BrainStorm Announces the Mount Sinai Medical Center as a Progressive MS Phase 2 Clinical Trial Site
NEW YORK , Nov. 25, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, today announced that The Mount Sinai Medical Center, internationally acclaimed for its
View HTML
Toggle Summary BrainStorm Cell Therapeutics Announces Publication of NurOwn® ALS Phase 2 Randomized Clinical Trial Data in Neurology
A single transplantation of MSC-NTF cells (NurOwn®) in ALS clinical trial participants met the primary safety endpoint and demonstrated promising stabilization of ALS disease progression of up to 12-16 weeks in a prespecified subgroup of ALS rapid progressors Cerebrospinal fluid (CSF) analysis
View HTML
Toggle Summary BrainStorm Cell Therapeutics Announces Research Grant Award From the National Multiple Sclerosis Society
NEW YORK , Nov. 14, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc . ( NASDAQ:BCLI ), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that the Company has received a $495,330 grant from the National Multiple Sclerosis Society , through
View HTML
Toggle Summary BrainStorm Announces Financial Results for the Third Quarter of 2019 and Provides a Corporate Update
Conference Call and Webcast Today at 8:00 a.m. Eastern Time Highlights Include: ALS Phase 3 Clinical Trial Fully Enrolled, Data Safety Monitoring Board Recommends ALS Phase 3 Clinical Trial Continue, Appointment of CFO, Phase 2 in Progressive MS Continues to Enroll Patients   NEW YORK , Nov.
View HTML
Toggle Summary BrainStorm Announces Grant of a New Japanese Patent for NurOwn®
NEW YORK , Nov. 13, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc.  ( NASDAQ: BCLI ), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the Japan Patent Office (JPO) has issued a Decision to Grant a Patent for BrainStorm's Patent
View HTML
Toggle Summary BrainStorm Cell Therapeutics Announces Ralph Kern MD MHSc to Present at the 7th International Stem Cell Meeting
NEW YORK , Nov. 12, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc . ( NASDAQ:BCLI ), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the Company’s Chief Operating and Chief Medical Officer Ralph Kern MD MHSc will present at the 7 th
View HTML
Toggle Summary BrainStorm Cell Therapeutics to Announce Third Quarter Financial Results and Provide a Comprehensive Corporate Update
NEW YORK , Nov. 05, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc . ( NASDAQ:BCLI ), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the Company will hold a conference call to update shareholders on financial results for the third
View HTML
Toggle Summary NurOwn® Data Safety Monitoring Board Recommends ALS Phase 3 Clinical Trial Continue
NEW YORK , Oct. 28, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc . ( NASDAQ: BCLI ), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the Phase 3 clinical trial independent Data Safety Monitoring Board (DSMB) has completed the
View HTML
Toggle Summary BrainStorm Cell Therapeutics to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference
NEW YORK , Oct. 25, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leader in the development of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, today announced that it will be presenting at the Dawson James Securities 5th
View HTML
Toggle Summary BrainStorm Cell Therapeutics’ President and CEO to be Featured as Keynote Speaker at Cell Series UK 2019
NEW YORK , Oct. 24, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leader in the development of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, today announced, Chaim Lebovits , President and CEO, will serve as a Keynote
View HTML
Toggle Summary BrainStorm Cell Therapeutics Presentations at Neuromuscular Drug Development Summit
NEW YORK , Oct. 23, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leader in the development of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, will be participating and presenting scientific data at the upcoming
View HTML
Toggle Summary BrainStorm’s NurOwn® Phase 3 ALS Clinical Trial Now Fully Enrolled
NEW YORK , Oct. 11, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc . ( NASDAQ: BCLI ), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that it has fully enrolled the 200-patient Phase 3 clinical trial evaluating repeat intrathecal
View HTML
Toggle Summary BrainStorm Announces Notice of US Patent Allowance for NurOwn® Cellular Therapeutic Technology Platform
NEW YORK , Oct. 07, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc.  ( NASDAQ: BCLI ), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the United States Patent and Trademark Office ( USPTO ) has issued a Notice of Allowance for
View HTML
Toggle Summary BrainStorm Cell Therapeutics to Present NurOwn® Phase 2 Biomarker Data at North East Amyotrophic Lateral Sclerosis (NEALS) 18th Annual Meeting
NEW YORK , Oct. 02, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leader in the development of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases announced today, Chief Operating Officer and Chief Medical Officer, Ralph Kern
View HTML
Toggle Summary BrainStorm Cell Therapeutics Announces Support for FDA Guidelines on ALS Drug Development
BrainStorm Holds a Roundtable Discussion with ALS Advocacy Group Leaders   NEW YORK , Sept. 27, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leader in the development of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases
View HTML
Toggle Summary BrainStorm Strengthens Senior Executive Management Team with the Appointment of Preetam Shah, Ph.D., M.B.A., as Chief Financial Officer
NEW YORK , Sept. 09, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that Preetam Shah , Ph.D., M.B.A., has been appointed Chief Financial Officer effective September 6 ,
View HTML
Toggle Summary BrainStorm Cell Therapeutics to Present Late Breaking News ePoster at the 35th ECTRIMS Congress
NEW YORK , Sept. 06, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leader in the development of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, will present scientific data at the 35 th Congress of the European Committee
View HTML
Toggle Summary BrainStorm Announces Financial Results for the Second Quarter of 2019 and Provides a Corporate Update
Conference Call and Webcast Today at 8:00 a.m. Eastern Time Highlights Include: Special High -level FDA Meeting, Continued Progress in NurOwn ® ALS Phase 3 Trial and Progressive MS Phase 2 Trial, ALS Phase 3 Trial Enrollment Update NEW YORK , Aug. 13, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell
View HTML
Toggle Summary BrainStorm Cell Therapeutics to Announce Second Quarter Financial Results and Provide a Comprehensive Corporate Update
Tuesday, August 13, 2019, 8:00 a.m. EDT NEW YORK , Aug. 05, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today, that the Company will hold a
View HTML
Toggle Summary Third Clinical Site Initiated for BrainStorm Cell Therapeutic’s Phase 2 Progressive MS Study
NEW YORK , July 02, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today that the Company has contracted with the Keck School of Medicine of
View HTML
Toggle Summary BrainStorm Presents Poster at Consortium of Multiple Sclerosis Centers (CMSC) 33rd Annual Meeting
Design of Phase 2 Open-Label Multicenter Study in Progressive MS Outlined NEW YORK and SEATTLE , May 31, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases,
View HTML
Toggle Summary BrainStorm Announces Second Clinical Site to Enroll Patients in Its Progressive MS Phase 2 Study
NEW YORK , May 30, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, today announced that the Stanford University School of Medicine will serve as the
View HTML
Toggle Summary BrainStorm Issues Statement (Italian Translation Included)
Toggle Summary BrainStorm Senior Management to Present at BIO 2019
- Chaim Lebovits , President & CEO Corporate Presentation, June 4, 2019 -  - Ralph Kern MD, MHSc, Chief Medical Officer & Chief Operating Officer Round Table Panelist, June 4, 2019 - NEW YORK , May 28, 2019 (GLOBE NEWSWIRE) -- BrainStorm-Cell Therapeutics Inc.
View HTML
Toggle Summary BrainStorm CEO to Present at the World Advanced Therapy and Regenerative Medicine Congress in London
NEW YORK and LONDON , May 13, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( Nasdaq: BCLI ), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chaim Lebovits , president and CEO, will provide an update on the Company’s two
View HTML
Toggle Summary BrainStorm Announces Financial Results for the First Quarter of 2019 and Provides a Corporate Update
Highlights Scientific Advances and Continued Progress in NurOwn ® ALS Phase 3 Trial  and Progressive MS Phase 2 Trial; Expansion of the proprietary cellular technology platform NEW YORK , May 10, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc.
View HTML
Toggle Summary BrainStorm’s Cellular Technology Platform Expanded to Include Exosomes for Neurodegenerative Diseases
NEW YORK , April 30, 2019 (GLOBE NEWSWIRE) -- Brainstorm-Cell Therapeutics Inc. , ( NASDAQ: BCLI ), a leading developer of adult stem cell therapeutics for neurodegenerative disease, today announced that it has expanded its proprietary cellular technology platform to include NurOwn®-derived
View HTML
Toggle Summary Two BrainStorm Scientific Abstracts Accepted for Presentation at the 71st American Academy of Neurology Annual Meeting
Abstracts to highlight NurOwn® mechanism of action and correlation of Phase 2 clinical outcomes with ALS disease biomarkers NEW YORK , March 28, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc.  ( NASDAQ: BCLI ), a leader in developing innovative autologous cellular therapies for highly
View HTML
Toggle Summary BrainStorm Announces Grant of an additional New European Patent for NurOwn®
NEW YORK , March 26, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc.  ( NASDAQ: BCLI ), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the European Patent Office ("EPO") has granted a European-wide patent titled 'Mesenchymal Stem
View HTML
Toggle Summary BrainStorm Announces First Patient Enrolled in Phase 2 Clinical Trial of Progressive MS
Enrollment Announced During MS Awareness Week NEW YORK and CLEVELAND , March 14, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc.  ( NASDAQ: BCLI ), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today that the
View HTML
Toggle Summary BrainStorm to Host Business Update Conference Call
Tuesday, March 12th at 8.30am EDT NEW YORK , March 07, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc.  ( NASDAQ: BCLI ), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, will hold a conference call on Tuesday, March 12
View HTML
Toggle Summary BrainStorm Announces First Contracted U.S. Clinical Site for Phase 2 Progressive MS Study
Phase 2 Open-Label Trial of Autologous MSC-NTF Cell Therapy (NurOwn®) in Progressive MS Patients will Begin Enrollment in Early 2019 NEW YORK and CLEVELAND , Feb. 22, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc.  ( NASDAQ: BCLI ), a leader in developing innovative autologous cellular
View HTML
Toggle Summary BrainStorm to Present at 2019 Sachs Associates European Life Sciences CEO Forum in Zurich, Switzerland
ZURICH, Switzerland and NEW YORK , Feb. 21, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today that Chaim Lebovits , CEO will present at the
View HTML
Toggle Summary BrainStorm Issues a Statement to Patients and Shareholders
NEW YORK , Feb. 19, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, in response to numerous requests, issues today the following statement: We will begin by
View HTML
Toggle Summary BrainStorm to Present at 2019 BIO CEO & Investor Conference and Extracellular Vesicles in Diagnostics & Therapeutics Symposium
NEW YORK , Feb. 04, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today that Chaim Lebovits , CEO, will provide a corporate presentation at the
View HTML
Toggle Summary BrainStorm Cell Therapeutics to Present at the 2019 NobleCon15 Annual Investor Conference in Fort Lauderdale, Florida
NEW YORK , Jan. 25, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today that Chaim Lebovits , CEO will provide a corporate overview presentation
View HTML
Toggle Summary BrainStorm Granted Additional Patent for NurOwn® in Israel
NEW YORK , Jan. 22, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for debilitating neurodegenerative diseases, today announced that the Israel Patent Office has granted an additional patent titled “Methods
View HTML
Toggle Summary BrainStorm to Present NurOwn® Phase 3 Study Update at the 9th Annual California ALS Research Summit in Irvine, CA
Dr. Ralph Kern to Provide Update on the Phase 3 Pivotal Trial of Autologous MSC-NTF Cellular Therapy (NurOwn®) in ALS   NEW YORK and IRVINE, Calif. , Jan. 11, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc.  (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies
View HTML
Toggle Summary BrainStorm Cell Therapeutics to Present at the 2019 Biotech Showcase and Sachs Associates Neuroscience Innovation Forum at JPM Week
NEW YORK , Jan. 03, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Chaim Lebovits , President and Chief Executive Officer, will provide a corporate overview at the
View HTML
Tools
Email Alerts
Investor Contact
Investor FAQs
RSS Feeds